Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 72

Sort by

Sort Order Select

Journal Articles

Symptom Burden in Idiopathic Multicentric Castleman Disease: Protocol for the Development of a Novel Standardized Patient Reported Outcome Measure

Sudipto Mukherjee, Philip A Powell, Jill Carlton, Clara Murukia, Antonio Adolfo Guerra Soares Brandão, Karthik Ramasamy, Frankie Shupo, Grace Wayi-Wayi, Karan Kanhai, Kelley C Dacus, Kelly Makarounas-Kirchmann, Anju Devianee Keetharuth

Blood (2023) 142 (Supplement 1): 7342.

https://doi.org/10.1182/blood-2023-186256

Published: 2023

Journal Articles

RADAR Trial: MRD Response Adapted Trial for Newly Diagnosed Transplant Eligible Myeloma Patients

Blood (2023) 142 (Supplement 1): 3390.

https://doi.org/10.1182/blood-2023-188844

Published: 2023

Journal Articles

High Neoantigen Load Confers a Major Benefit from Autologous Stem Cell Transplantation Compared to Consolidation in Newly Diagnosed Multiple Myeloma

Blood (2023) 142 (Supplement 1): 3306.

https://doi.org/10.1182/blood-2023-186318

Published: 2023

Journal Articles

Using Mass Spectrometry to Assess Disease Status in Treated Multiple Myeloma Patients

Lauren Campbell, Karthik Ramasamy, Ross Sadler

Blood (2023) 142 (Supplement 1): 2001.

https://doi.org/10.1182/blood-2023-190768

Published: 2023

Journal Articles

Targeted NGS Panel Guides Risk-Adapted Treatment Intention in Newly Diagnosed Myeloma Patients

Gaurav Agarwal, Mohammad Kazeroun, Mirian Salazar, Khrystal McBean, Lisa Ferguson, Jemma Larham, Jaimal Kothari, Naser Ansari-Pour, Sally Moore, Eileen Boyle, Udo Oppermann, Karthik Ramasamy, Angela Hamblin, Anjan Thakurta, Sarah Gooding

Blood (2023) 142 (Supplement 1): 644.

https://doi.org/10.1182/blood-2023-182734

Published: 2023

Journal Articles

Non-Invasive MRD Monitoring in Multiple Myeloma Patients By Heavy/Light Chain Analysis

Lauren Campbell, Karthik Ramasamy, Ross Sadler

Blood (2023) 142 (Supplement 1): 4716.

https://doi.org/10.1182/blood-2023-190487

Published: 2023

Journal Articles

Health-Related Quality of Life (HRQoL) in Patients with Genetic Standard and High-Risk Disease at Trial Entry: A Cross-Sectional Analysis of RADAR (UK-MRA Myeloma XV)

Blood (2023) 142 (Supplement 1): 4710.

https://doi.org/10.1182/blood-2023-187453

Published: 2023

Journal Articles

Acquisition of 1pLOH-1qGain Is a Frequent Trajectory in Expanding Relapsed/Refractory Myeloma Subclones

Naser Ansari-Pour, Mohammad Kazeroun, Evie Fitzsimons, Selina J Chavda, Alessandro Lagana, Erin Flynt, Udo Oppermann, Karthik Ramasamy, Kwee Yong, Sarah Gooding, Anjan Thakurta

Blood (2023) 142 (Supplement 1): 1999.

https://doi.org/10.1182/blood-2023-190584

Published: 2023

Journal Articles

Treatment Patterns and Outcomes for Patients with Newly Diagnosed Multiple Myeloma Post-Stem Cell Transplantation Who Received Lenalidomide As First Line Maintenance Therapy (PREAMBLE)

Ravi Vij, Suvina Amin, Jin Gu, Thomas S. Marshall, Susan Fish, Sujith Dhanasiri, Gabriela Hernandez, David Cella, Hartmut Goldschmidt, Karthik Ramasamy

Blood (2023) 142 (Supplement 1): 3786.

https://doi.org/10.1182/blood-2023-178500

Published: 2023

Journal Articles

High Throughput Risk-Adapted Monoclonal Gammopathy Community Monitoring Program

Gaurav Agarwal, Lauren Campbell, Oluremi Carty, Sally Moore, Sarah Gooding, Jaimal Kothari, Julia Evans, Jemma Larham, Lisa Ferguson, Pamela Roberts, Elizabeth Bateman, Ross Sadler, Karthik Ramasamy

Blood (2023) 142 (Supplement 1): 5077.

https://doi.org/10.1182/blood-2023-190444

Published: 2023

Journal Articles

Network Meta-Analysis of Randomized Trials in Relapsed/Refractory Multiple Myeloma: Relative Efficacy for Patients Who Are Lenalidomide-Refractory

Efstathios Kastritis, Rebecca Harvey, Holly Cranmer, Martina Bianco, Elisabetta Fenu, Charles La Porte, Karthik Ramasamy

Blood (2023) 142 (Supplement 1): 7424.

https://doi.org/10.1182/blood-2023-180947

Published: 2023

Journal Articles

High Success Rates Utilizing Local Standard of Care Cytogenetic Testing for Risk Stratified Frontline Therapy for Newly Diagnosed Multiple Myeloma: Experience from the Ukmra RADAR Study

Blood (2023) 142 (Supplement 1): 6715.

https://doi.org/10.1182/blood-2023-188697

Published: 2023

Journal Articles

Flicking the switch in myeloma MRD

Edmund Watson, Karthik Ramasamy

Blood (2023) 141 (6): 557–558.

https://doi.org/10.1182/blood.2022018394

Published: 2023

Journal Articles

Mezigdomide (CC-92480), a Potent, Novel Cereblon E3 Ligase Modulator (CELMoD), Combined with Dexamethasone (DEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results from the Dose-Expansion Phase of the CC-92480-MM-001 Trial

Paul G. Richardson, Suzanne Trudel, Hang Quach, Rakesh Popat, Sagar Lonial, Robert Z. Orlowski, Kihyun Kim, María-Victoria Mateos, Charlotte Pawlyn, Karthik Ramasamy, Joaquín Martinez-Lopez, Alessia Spirli, Ignacio Casas-Avilés, Jing Gong, Michael Amatangelo, Jessica Katz, Paulo Maciag, Teresa Peluso, Nizar J. Bahlis

Blood (2022) 140 (Supplement 1): 1366–1368.

https://doi.org/10.1182/blood-2022-157945

Published: 2022

Journal Articles

Health-Related Quality of Life for Frail Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide and Dexamethasone: Subgroup Analysis of MAIA Trial

Blood (2022) 140 (Supplement 1): 1142–1145.

https://doi.org/10.1182/blood-2022-165524

Published: 2022

Journal Articles

Risk-Adapted Therapy Directed According to Response (RADAR, UK-MRA Myeloma XV) - Comparing MRD-Guided Treatment Escalation and De-Escalation Strategies in Patients with Newly Diagnosed Myeloma Suitable for Stem Cell Transplantation

Blood (2022) 140 (Supplement 1): 1844–1846.

https://doi.org/10.1182/blood-2022-168842

Published: 2022

Journal Articles

Artificial Intelligence-Based Quantitative and Topological Analysis of Plasma Cell Burden: A New Tool for the Assessment of Myeloma

Oliver C. Lomas, Daniel Royston, Hosuk Ryou, Alan Aberdeen, Korsuk Sirinukunwattana, Karthik Ramasamy, Sarah Gooding, Jemma Larham

Blood (2022) 140 (Supplement 1): 12603–12604.

https://doi.org/10.1182/blood-2022-158525

Published: 2022

Journal Articles

Safety and Survival Outcomes in the Non-Interventional Post-Authorization Study of Patients Treated with Pomalidomide for Relapsed and Refractory Multiple Myeloma: A Sub-Analysis of Patients with Prior Triple Class Exposure

Karthik Ramasamy, Niels Abildgaard, Marie-Christiane Vekemans, Barbara Gamberi, Angel Ramírez Payer, Gillian Millar, Annalisa Ansaloni, Margaret Atiba-Davies, David Bernasconi, Torben Plesner, Sujith Dhanasiri

Blood (2022) 140 (Supplement 1): 10000–10001.

https://doi.org/10.1182/blood-2022-162529

Published: 2022

Journal Articles

Developing a Flow Cytometric Signature of Carfilzomib Responsiveness in Myeloma

Blood (2022) 140 (Supplement 1): 10106–10107.

https://doi.org/10.1182/blood-2022-169882

Published: 2022

Journal Articles

Isatuximab with Pomalidomide and Dexamethasone Provides Comparable Efficacy Outcomes in Frail Routine Care Myeloma Patients in a UK-Wide Cohort

Blood (2022) 140 (Supplement 1): 5206–5207.

https://doi.org/10.1182/blood-2022-163025

Published: 2022

NARROW

Symptom Burden in Idiopathic Multicentric Castleman Disease: Protocol for the Development of a Novel Standardized Patient Reported Outcome Measure

RADAR Trial: MRD Response Adapted Trial for Newly Diagnosed Transplant Eligible Myeloma Patients

High Neoantigen Load Confers a Major Benefit from Autologous Stem Cell Transplantation Compared to Consolidation in Newly Diagnosed Multiple Myeloma

Using Mass Spectrometry to Assess Disease Status in Treated Multiple Myeloma Patients

Targeted NGS Panel Guides Risk-Adapted Treatment Intention in Newly Diagnosed Myeloma Patients

Non-Invasive MRD Monitoring in Multiple Myeloma Patients By Heavy/Light Chain Analysis

Health-Related Quality of Life (HRQoL) in Patients with Genetic Standard and High-Risk Disease at Trial Entry: A Cross-Sectional Analysis of RADAR (UK-MRA Myeloma XV)

Acquisition of 1pLOH-1qGain Is a Frequent Trajectory in Expanding Relapsed/Refractory Myeloma Subclones

Treatment Patterns and Outcomes for Patients with Newly Diagnosed Multiple Myeloma Post-Stem Cell Transplantation Who Received Lenalidomide As First Line Maintenance Therapy (PREAMBLE)

High Throughput Risk-Adapted Monoclonal Gammopathy Community Monitoring Program

Network Meta-Analysis of Randomized Trials in Relapsed/Refractory Multiple Myeloma: Relative Efficacy for Patients Who Are Lenalidomide-Refractory

High Success Rates Utilizing Local Standard of Care Cytogenetic Testing for Risk Stratified Frontline Therapy for Newly Diagnosed Multiple Myeloma: Experience from the Ukmra RADAR Study

Flicking the switch in myeloma MRD

Mezigdomide (CC-92480), a Potent, Novel Cereblon E3 Ligase Modulator (CELMoD), Combined with Dexamethasone (DEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results from the Dose-Expansion Phase of the CC-92480-MM-001 Trial

Health-Related Quality of Life for Frail Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide and Dexamethasone: Subgroup Analysis of MAIA Trial

Risk-Adapted Therapy Directed According to Response (RADAR, UK-MRA Myeloma XV) - Comparing MRD-Guided Treatment Escalation and De-Escalation Strategies in Patients with Newly Diagnosed Myeloma Suitable for Stem Cell Transplantation

Artificial Intelligence-Based Quantitative and Topological Analysis of Plasma Cell Burden: A New Tool for the Assessment of Myeloma

Safety and Survival Outcomes in the Non-Interventional Post-Authorization Study of Patients Treated with Pomalidomide for Relapsed and Refractory Multiple Myeloma: A Sub-Analysis of Patients with Prior Triple Class Exposure

Developing a Flow Cytometric Signature of Carfilzomib Responsiveness in Myeloma

Isatuximab with Pomalidomide and Dexamethasone Provides Comparable Efficacy Outcomes in Frail Routine Care Myeloma Patients in a UK-Wide Cohort

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only